BioCentury
ARTICLE | Company News

ASCO recommends MammaPrint to inform chemo use

July 10, 2017 10:36 PM UTC

In an update to its clinical practice guidelines for women with early breast cancer in the adjuvant setting, the American Society of Clinical Oncology recommended use of the MammaPrint test to identify women who need chemotherapy and those who do not.

Agendia N.V. (Amsterdam, the Netherlands) markets MammaPrint, a 70-gene signature chip, to assess the risk of breast cancer recurrence...